Skip to main content

New Y-90 Data & Evolution Towards Super-Selective Treatment

New Y-90 Data & Evolution Towards Super-Selective Treatment

Pavan Khanna

Pavan Khanna, MD, Chair and Medical Director of the Department of Diagnostic and Interventional Radiology at St. Joseph’s Medical Center in Stockton, California, discusses the evolution of Y-90 for the treatment of hepatocellular carcinoma (HCC). Dr Khanna also reviews the data from the LEGACY and DOSISPHERE trials, which highlight how TheraSphere™ is progressing Y-90 therapy towards more advanced dosimetry techniques and personalization.

Back to Top